Estimation of Anti-SARS-CoV-2 IgM/IgG Seroprevalence Among Non-Vaccinated and Vaccinated University Students: A Cross-Sectional Egyptian Study

It is essential to comprehend the humoral immune response to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its vaccines to maximize the effectiveness of anti-SARSCoV-2 community immunization efforts. The aim of this cross-sectional study was to determine the seroprevalence of anti...

Full description

Saved in:
Bibliographic Details
Published inViruses Vol. 17; no. 3; p. 378
Main Authors Taha, Ahmed E., Amer, Ibrahim, Sharawy, Shimaa El, Ghazy, Amany A.
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 06.03.2025
MDPI
Subjects
Online AccessGet full text

Cover

Loading…
Abstract It is essential to comprehend the humoral immune response to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its vaccines to maximize the effectiveness of anti-SARSCoV-2 community immunization efforts. The aim of this cross-sectional study was to determine the seroprevalence of anti-SARS-CoV-2 IgM/IgG among newcomer students at Kafr Elsheikh University in Egypt, whether they had been vaccinated or not. Blood samples from 400 healthy newcomer students (200 non-vaccinated and 200 vaccinated) were evaluated for the presence of anti-SARS-CoV-2 IgM/IgG using colloidal gold immunochromatography lateral flow immunoassay cards, and then the results were confirmed by using specific ELISA tests. The prevalence of anti-SARS-CoV-2 antibodies among the participants (n = 400) was 56.3% for IgG and 13.3% for IgM. Regarding the non-vaccinated participants, 55.0% were females, the mean age was 18.2 years, and the mean BMI was 25.35. Regarding the vaccinated participants, 58.5% were females, the mean age was 18.1 years, and the mean BMI was 25.3. There were statistically non-significant correlations (p ˃ 0.05) between gender, BMI, and each of IgM- or IgG-positivity in both vaccinated and non-vaccinated groups. In total, 41.5% and 48.5% of the anti-SARS-CoV-2 IgM-positive and anti-SARS-CoV-2 IgG-positive participants were non-vaccinated, respectively. Furthermore, 58.5% and 51.5% of the anti-SARS-CoV-2 IgM-positive and anti-SARS-CoV-2 IgG-positive participants were vaccinated, respectively. No statistically significant association (p ˃ 0.05) in immunoglobulins positivity between the anti-SARS-CoV-2 non-vaccinated, and vaccinated groups. The anti-SARS-CoV-2 immunological response of nonsmokers, people who exercise regularly, and those who take vitamin supplements, eat a balanced diet, and use certain herbs is noteworthy. Among the vaccinated subjects, 96.6%, 25.0%, 31.9%, 45.7%, and 7.8% of the IgG-positive group, versus 97.2%, 60.6%, 64.2%, 52.3%, and 6.4% of the IgG-positive non-vaccinated group, were nonsmokers, exercisers, and those taking vitamin supplements, eating a balanced diet, and using herbs, respectively. Furthermore, 93.5%, 32.3%, 35.5%, 48.4%, and 6.5% of the IgM-positive vaccinated group, versus 100.0%, 63.6%, 81.8%, 45.5%, and 4.5% of the IgM-positive non-vaccinated participants, were nonsmokers, physical exercisers, vitamin supplement users, balanced eaters, and herbalists, respectively. Persons who are free from comorbidities, young, non-obese, non-smokers, engage in physical exercise, take vitamins, eat a balanced diet, and use certain immunostimulant herbal supplements, all have a strong anti-SARS-CoV-2 humoral immune response, even if they were not vaccinated. During pandemics, vaccination of this group should not be a priority to preserve vaccine doses for high-risk vulnerable people. Even if there is a lockdown during an anticipated future epidemic or pandemic, we should prioritize healthy eating and lifestyle choices, along with increasing physical activity.
AbstractList It is essential to comprehend the humoral immune response to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its vaccines to maximize the effectiveness of anti-SARSCoV-2 community immunization efforts. The aim of this cross-sectional study was to determine the seroprevalence of anti-SARS-CoV-2 IgM/IgG among newcomer students at Kafr Elsheikh University in Egypt, whether they had been vaccinated or not. Blood samples from 400 healthy newcomer students (200 non-vaccinated and 200 vaccinated) were evaluated for the presence of anti-SARS-CoV-2 IgM/IgG using colloidal gold immunochromatography lateral flow immunoassay cards, and then the results were confirmed by using specific ELISA tests. The prevalence of anti-SARS-CoV-2 antibodies among the participants (n = 400) was 56.3% for IgG and 13.3% for IgM. Regarding the non-vaccinated participants, 55.0% were females, the mean age was 18.2 years, and the mean BMI was 25.35. Regarding the vaccinated participants, 58.5% were females, the mean age was 18.1 years, and the mean BMI was 25.3. There were statistically non-significant correlations (p ˃ 0.05) between gender, BMI, and each of IgM- or IgG-positivity in both vaccinated and non-vaccinated groups. In total, 41.5% and 48.5% of the anti-SARS-CoV-2 IgM-positive and anti-SARS-CoV-2 IgG-positive participants were non-vaccinated, respectively. Furthermore, 58.5% and 51.5% of the anti-SARS-CoV-2 IgM-positive and anti-SARS-CoV-2 IgG-positive participants were vaccinated, respectively. No statistically significant association (p ˃ 0.05) in immunoglobulins positivity between the anti-SARS-CoV-2 non-vaccinated, and vaccinated groups. The anti-SARS-CoV-2 immunological response of nonsmokers, people who exercise regularly, and those who take vitamin supplements, eat a balanced diet, and use certain herbs is noteworthy. Among the vaccinated subjects, 96.6%, 25.0%, 31.9%, 45.7%, and 7.8% of the IgG-positive group, versus 97.2%, 60.6%, 64.2%, 52.3%, and 6.4% of the IgG-positive non-vaccinated group, were nonsmokers, exercisers, and those taking vitamin supplements, eating a balanced diet, and using herbs, respectively. Furthermore, 93.5%, 32.3%, 35.5%, 48.4%, and 6.5% of the IgM-positive vaccinated group, versus 100.0%, 63.6%, 81.8%, 45.5%, and 4.5% of the IgM-positive non-vaccinated participants, were nonsmokers, physical exercisers, vitamin supplement users, balanced eaters, and herbalists, respectively. Persons who are free from comorbidities, young, non-obese, non-smokers, engage in physical exercise, take vitamins, eat a balanced diet, and use certain immunostimulant herbal supplements, all have a strong anti-SARS-CoV-2 humoral immune response, even if they were not vaccinated. During pandemics, vaccination of this group should not be a priority to preserve vaccine doses for high-risk vulnerable people. Even if there is a lockdown during an anticipated future epidemic or pandemic, we should prioritize healthy eating and lifestyle choices, along with increasing physical activity.It is essential to comprehend the humoral immune response to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its vaccines to maximize the effectiveness of anti-SARSCoV-2 community immunization efforts. The aim of this cross-sectional study was to determine the seroprevalence of anti-SARS-CoV-2 IgM/IgG among newcomer students at Kafr Elsheikh University in Egypt, whether they had been vaccinated or not. Blood samples from 400 healthy newcomer students (200 non-vaccinated and 200 vaccinated) were evaluated for the presence of anti-SARS-CoV-2 IgM/IgG using colloidal gold immunochromatography lateral flow immunoassay cards, and then the results were confirmed by using specific ELISA tests. The prevalence of anti-SARS-CoV-2 antibodies among the participants (n = 400) was 56.3% for IgG and 13.3% for IgM. Regarding the non-vaccinated participants, 55.0% were females, the mean age was 18.2 years, and the mean BMI was 25.35. Regarding the vaccinated participants, 58.5% were females, the mean age was 18.1 years, and the mean BMI was 25.3. There were statistically non-significant correlations (p ˃ 0.05) between gender, BMI, and each of IgM- or IgG-positivity in both vaccinated and non-vaccinated groups. In total, 41.5% and 48.5% of the anti-SARS-CoV-2 IgM-positive and anti-SARS-CoV-2 IgG-positive participants were non-vaccinated, respectively. Furthermore, 58.5% and 51.5% of the anti-SARS-CoV-2 IgM-positive and anti-SARS-CoV-2 IgG-positive participants were vaccinated, respectively. No statistically significant association (p ˃ 0.05) in immunoglobulins positivity between the anti-SARS-CoV-2 non-vaccinated, and vaccinated groups. The anti-SARS-CoV-2 immunological response of nonsmokers, people who exercise regularly, and those who take vitamin supplements, eat a balanced diet, and use certain herbs is noteworthy. Among the vaccinated subjects, 96.6%, 25.0%, 31.9%, 45.7%, and 7.8% of the IgG-positive group, versus 97.2%, 60.6%, 64.2%, 52.3%, and 6.4% of the IgG-positive non-vaccinated group, were nonsmokers, exercisers, and those taking vitamin supplements, eating a balanced diet, and using herbs, respectively. Furthermore, 93.5%, 32.3%, 35.5%, 48.4%, and 6.5% of the IgM-positive vaccinated group, versus 100.0%, 63.6%, 81.8%, 45.5%, and 4.5% of the IgM-positive non-vaccinated participants, were nonsmokers, physical exercisers, vitamin supplement users, balanced eaters, and herbalists, respectively. Persons who are free from comorbidities, young, non-obese, non-smokers, engage in physical exercise, take vitamins, eat a balanced diet, and use certain immunostimulant herbal supplements, all have a strong anti-SARS-CoV-2 humoral immune response, even if they were not vaccinated. During pandemics, vaccination of this group should not be a priority to preserve vaccine doses for high-risk vulnerable people. Even if there is a lockdown during an anticipated future epidemic or pandemic, we should prioritize healthy eating and lifestyle choices, along with increasing physical activity.
It is essential to comprehend the humoral immune response to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its vaccines to maximize the effectiveness of anti-SARSCoV-2 community immunization efforts. The aim of this cross-sectional study was to determine the seroprevalence of anti-SARS-CoV-2 IgM/IgG among newcomer students at Kafr Elsheikh University in Egypt, whether they had been vaccinated or not. Blood samples from 400 healthy newcomer students (200 non-vaccinated and 200 vaccinated) were evaluated for the presence of anti-SARS-CoV-2 IgM/IgG using colloidal gold immunochromatography lateral flow immunoassay cards, and then the results were confirmed by using specific ELISA tests. The prevalence of anti-SARS-CoV-2 antibodies among the participants ( n = 400) was 56.3% for IgG and 13.3% for IgM. Regarding the non-vaccinated participants, 55.0% were females, the mean age was 18.2 years, and the mean BMI was 25.35. Regarding the vaccinated participants, 58.5% were females, the mean age was 18.1 years, and the mean BMI was 25.3. There were statistically non-significant correlations ( p ˃ 0.05) between gender, BMI, and each of IgM- or IgG-positivity in both vaccinated and non-vaccinated groups. In total, 41.5% and 48.5% of the anti-SARS-CoV-2 IgM-positive and anti-SARS-CoV-2 IgG-positive participants were non-vaccinated, respectively. Furthermore, 58.5% and 51.5% of the anti-SARS-CoV-2 IgM-positive and anti-SARS-CoV-2 IgG-positive participants were vaccinated, respectively. No statistically significant association ( p ˃ 0.05) in immunoglobulins positivity between the anti-SARS-CoV-2 non-vaccinated, and vaccinated groups. The anti-SARS-CoV-2 immunological response of nonsmokers, people who exercise regularly, and those who take vitamin supplements, eat a balanced diet, and use certain herbs is noteworthy. Among the vaccinated subjects, 96.6%, 25.0%, 31.9%, 45.7%, and 7.8% of the IgG-positive group, versus 97.2%, 60.6%, 64.2%, 52.3%, and 6.4% of the IgG-positive non-vaccinated group, were nonsmokers, exercisers, and those taking vitamin supplements, eating a balanced diet, and using herbs, respectively. Furthermore, 93.5%, 32.3%, 35.5%, 48.4%, and 6.5% of the IgM-positive vaccinated group, versus 100.0%, 63.6%, 81.8%, 45.5%, and 4.5% of the IgM-positive non-vaccinated participants, were nonsmokers, physical exercisers, vitamin supplement users, balanced eaters, and herbalists, respectively. Persons who are free from comorbidities, young, non-obese, non-smokers, engage in physical exercise, take vitamins, eat a balanced diet, and use certain immunostimulant herbal supplements, all have a strong anti-SARS-CoV-2 humoral immune response, even if they were not vaccinated. During pandemics, vaccination of this group should not be a priority to preserve vaccine doses for high-risk vulnerable people. Even if there is a lockdown during an anticipated future epidemic or pandemic, we should prioritize healthy eating and lifestyle choices, along with increasing physical activity.
It is essential to comprehend the humoral immune response to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its vaccines to maximize the effectiveness of anti-SARSCoV-2 community immunization efforts. The aim of this cross-sectional study was to determine the seroprevalence of anti-SARS-CoV-2 IgM/IgG among newcomer students at Kafr Elsheikh University in Egypt, whether they had been vaccinated or not. Blood samples from 400 healthy newcomer students (200 non-vaccinated and 200 vaccinated) were evaluated for the presence of anti-SARS-CoV-2 IgM/IgG using colloidal gold immunochromatography lateral flow immunoassay cards, and then the results were confirmed by using specific ELISA tests. The prevalence of anti-SARS-CoV-2 antibodies among the participants ( = 400) was 56.3% for IgG and 13.3% for IgM. Regarding the non-vaccinated participants, 55.0% were females, the mean age was 18.2 years, and the mean BMI was 25.35. Regarding the vaccinated participants, 58.5% were females, the mean age was 18.1 years, and the mean BMI was 25.3. There were statistically non-significant correlations ( ˃ 0.05) between gender, BMI, and each of IgM- or IgG-positivity in both vaccinated and non-vaccinated groups. In total, 41.5% and 48.5% of the anti-SARS-CoV-2 IgM-positive and anti-SARS-CoV-2 IgG-positive participants were non-vaccinated, respectively. Furthermore, 58.5% and 51.5% of the anti-SARS-CoV-2 IgM-positive and anti-SARS-CoV-2 IgG-positive participants were vaccinated, respectively. No statistically significant association ( ˃ 0.05) in immunoglobulins positivity between the anti-SARS-CoV-2 non-vaccinated, and vaccinated groups. The anti-SARS-CoV-2 immunological response of nonsmokers, people who exercise regularly, and those who take vitamin supplements, eat a balanced diet, and use certain herbs is noteworthy. Among the vaccinated subjects, 96.6%, 25.0%, 31.9%, 45.7%, and 7.8% of the IgG-positive group, versus 97.2%, 60.6%, 64.2%, 52.3%, and 6.4% of the IgG-positive non-vaccinated group, were nonsmokers, exercisers, and those taking vitamin supplements, eating a balanced diet, and using herbs, respectively. Furthermore, 93.5%, 32.3%, 35.5%, 48.4%, and 6.5% of the IgM-positive vaccinated group, versus 100.0%, 63.6%, 81.8%, 45.5%, and 4.5% of the IgM-positive non-vaccinated participants, were nonsmokers, physical exercisers, vitamin supplement users, balanced eaters, and herbalists, respectively. Persons who are free from comorbidities, young, non-obese, non-smokers, engage in physical exercise, take vitamins, eat a balanced diet, and use certain immunostimulant herbal supplements, all have a strong anti-SARS-CoV-2 humoral immune response, even if they were not vaccinated. During pandemics, vaccination of this group should not be a priority to preserve vaccine doses for high-risk vulnerable people. Even if there is a lockdown during an anticipated future epidemic or pandemic, we should prioritize healthy eating and lifestyle choices, along with increasing physical activity.
It is essential to comprehend the humoral immune response to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its vaccines to maximize the effectiveness of anti-SARSCoV-2 community immunization efforts. The aim of this cross-sectional study was to determine the seroprevalence of anti-SARS-CoV-2 IgM/IgG among newcomer students at Kafr Elsheikh University in Egypt, whether they had been vaccinated or not. Blood samples from 400 healthy newcomer students (200 non-vaccinated and 200 vaccinated) were evaluated for the presence of anti-SARS-CoV-2 IgM/IgG using colloidal gold immunochromatography lateral flow immunoassay cards, and then the results were confirmed by using specific ELISA tests. The prevalence of anti-SARS-CoV-2 antibodies among the participants (n = 400) was 56.3% for IgG and 13.3% for IgM. Regarding the non-vaccinated participants, 55.0% were females, the mean age was 18.2 years, and the mean BMI was 25.35. Regarding the vaccinated participants, 58.5% were females, the mean age was 18.1 years, and the mean BMI was 25.3. There were statistically non-significant correlations (p ˃ 0.05) between gender, BMI, and each of IgM- or IgG-positivity in both vaccinated and non-vaccinated groups. In total, 41.5% and 48.5% of the anti-SARS-CoV-2 IgM-positive and anti-SARS-CoV-2 IgG-positive participants were non-vaccinated, respectively. Furthermore, 58.5% and 51.5% of the anti-SARS-CoV-2 IgM-positive and anti-SARS-CoV-2 IgG-positive participants were vaccinated, respectively. No statistically significant association (p ˃ 0.05) in immunoglobulins positivity between the anti-SARS-CoV-2 non-vaccinated, and vaccinated groups. The anti-SARS-CoV-2 immunological response of nonsmokers, people who exercise regularly, and those who take vitamin supplements, eat a balanced diet, and use certain herbs is noteworthy. Among the vaccinated subjects, 96.6%, 25.0%, 31.9%, 45.7%, and 7.8% of the IgG-positive group, versus 97.2%, 60.6%, 64.2%, 52.3%, and 6.4% of the IgG-positive non-vaccinated group, were nonsmokers, exercisers, and those taking vitamin supplements, eating a balanced diet, and using herbs, respectively. Furthermore, 93.5%, 32.3%, 35.5%, 48.4%, and 6.5% of the IgM-positive vaccinated group, versus 100.0%, 63.6%, 81.8%, 45.5%, and 4.5% of the IgM-positive non-vaccinated participants, were nonsmokers, physical exercisers, vitamin supplement users, balanced eaters, and herbalists, respectively. Persons who are free from comorbidities, young, non-obese, non-smokers, engage in physical exercise, take vitamins, eat a balanced diet, and use certain immunostimulant herbal supplements, all have a strong anti-SARS-CoV-2 humoral immune response, even if they were not vaccinated. During pandemics, vaccination of this group should not be a priority to preserve vaccine doses for high-risk vulnerable people. Even if there is a lockdown during an anticipated future epidemic or pandemic, we should prioritize healthy eating and lifestyle choices, along with increasing physical activity.
Audience Academic
Author Amer, Ibrahim
Taha, Ahmed E.
Sharawy, Shimaa El
Ghazy, Amany A.
AuthorAffiliation 2 Medical Microbiology and Immunology Department, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt
3 Department of Hepatology, Gastroenterology and Infectious Diseases, Faculty of Medicine, Kafr Elsheikh University, Kafr Elsheikh 33516, Egypt; ebrahiem_amier@med.kfs.edu.eg
1 Microbiology and Immunology Unit, Department of Pathology, College of Medicine, Jouf University, Sakaka 72388, Saudi Arabia; aeattia@ju.edu.sa
4 Department of Tropical Medicine and Infectious Diseases, Faculty of Medicine, Tanta University, Tanta 31527, Egypt; shaimaa.elsharawy@med.tanta.edu.eg
AuthorAffiliation_xml – name: 2 Medical Microbiology and Immunology Department, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt
– name: 1 Microbiology and Immunology Unit, Department of Pathology, College of Medicine, Jouf University, Sakaka 72388, Saudi Arabia; aeattia@ju.edu.sa
– name: 4 Department of Tropical Medicine and Infectious Diseases, Faculty of Medicine, Tanta University, Tanta 31527, Egypt; shaimaa.elsharawy@med.tanta.edu.eg
– name: 3 Department of Hepatology, Gastroenterology and Infectious Diseases, Faculty of Medicine, Kafr Elsheikh University, Kafr Elsheikh 33516, Egypt; ebrahiem_amier@med.kfs.edu.eg
Author_xml – sequence: 1
  givenname: Ahmed E.
  orcidid: 0000-0002-5766-4495
  surname: Taha
  fullname: Taha, Ahmed E.
– sequence: 2
  givenname: Ibrahim
  orcidid: 0000-0003-3778-8826
  surname: Amer
  fullname: Amer, Ibrahim
– sequence: 3
  givenname: Shimaa El
  orcidid: 0000-0003-0308-8653
  surname: Sharawy
  fullname: Sharawy, Shimaa El
– sequence: 4
  givenname: Amany A.
  orcidid: 0000-0002-5603-1303
  surname: Ghazy
  fullname: Ghazy, Amany A.
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40143306$$D View this record in MEDLINE/PubMed
BookMark eNptks2O0zAQxyO0iP2AAy-ALHGBQ3bt2HFiLiiquruVFpAou1fLsSfBVWoXJ63Ul-CZcbalahGag8fjn_-j-bhMzpx3kCRvCb6mVOCbDSkwxbQoXyQXRAiRMkHysyP_PLns-wXGnAtcvErOGSaMUswvkt_TfrBLNVjvkG9Q5Qabzqvv83Tin9IMzdovN7P2Ds0h-FWAjerAaUDV0rsWffUufVJaW6cGMEg5g46uj85uIPR22KL5sDbghv4TqtAk-L5P56DHlKpD03a7Gqxyz9D2dfKyUV0Pb_bnVfJ4O_0xuU8fvt3NJtVDqpkQQ8oNzRUra1OLPCsZ1oCbXBScKVUDgM4YE7WmNeMmKzHNsyZvyhITXmTAQAh6lcx2usarhVyF2IKwlV5Z-RzwoZUqDFZ3IAnXLGO8NEZk0dGjbi6MKQyIHDSOWp93Wqt1vQSjY6VBdSeipy_O_pSt30hCBOMsGxU-7BWC_7WGfpBL22voOuXAr3tJSUnKDHORR_T9P-jCr0Ns5J6KtWZHVBsHJq1rfEysR1FZlbTkoxWRuv4PFc3A0uq4Yo2N8ZMP744rPZT4d50i8HEH6HHKAZoDQrAcV1UeVpX-AbYe2Nc
Cites_doi 10.1093/cid/ciaa344
10.3390/vaccines10091462
10.3389/fpubh.2022.825874
10.3390/vaccines10030414
10.1513/AnnalsATS.201706-447AW
10.1016/j.vaccine.2023.02.038
10.3389/fnut.2023.1152254
10.3389/fphar.2021.669362
10.1016/j.ejmech.2022.114175
10.3390/medsci12010011
10.3855/jidc.16572
10.1016/j.clinthera.2023.04.008
10.1177/20503121231158981
10.1089/met.2015.0095
10.3855/jidc.15825
10.1017/S0029665112000158
10.1016/j.talanta.2022.123409
10.3390/vaccines9091047
10.1002/jmv.27604
10.7762/cnr.2023.12.4.269
10.22207/JPAM.14.2.02
10.1001/jama.2022.0470
10.3389/fnut.2023.1161894
10.1007/978-1-0716-1884-4_2
10.1128/spectrum.01181-21
10.3390/vaccines10020292
10.1016/j.heliyon.2023.e21205
10.1016/j.maturitas.2020.08.007
10.3389/fimmu.2021.737083
10.1016/j.jtct.2022.01.019
10.1093/trstmh/tru167
10.1097/MD.0000000000029438
10.1111/bcpt.13872
10.1002/ajh.26385
10.1002/cti2.1379
10.4239/wjd.v14.i6.892
10.1186/s12916-022-02547-2
10.1128/mSphere.00019-21
10.1016/j.heliyon.2023.e20792
10.1016/j.biopha.2021.111254
10.1093/aje/kwaa191
10.3390/vaccines11010026
10.3390/ijerph19127119
10.1016/j.vaccine.2021.10.038
10.15252/emmm.202216345
10.3390/ijerph192416803
10.1038/s41385-022-00569-w
10.1016/j.puhe.2023.03.013
10.1016/j.vaccine.2021.11.051
10.3389/fendo.2022.898810
10.1016/S2213-2600(20)30239-3
10.1038/s41577-020-0359-5
10.3389/fmed.2021.778129
10.1177/00220345211020270
10.1038/s41590-021-01080-3
10.1172/JCI138759
10.3389/fimmu.2021.802858
10.3201/eid2702.201960
10.3390/ijerph20065183
10.1016/j.molimm.2023.03.007
10.7326/M21-4176
10.1007/s11481-020-09974-z
10.7717/peerj.15072
10.1001/jamainternmed.2023.0750
10.1093/ije/dyab010
10.22207/JPAM.14.4.06
10.1002/jmv.27098
10.1186/s13054-020-02952-0
ContentType Journal Article
Copyright COPYRIGHT 2025 MDPI AG
2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2025 by the authors. 2025
Copyright_xml – notice: COPYRIGHT 2025 MDPI AG
– notice: 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2025 by the authors. 2025
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7U9
7X7
7XB
88E
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
COVID
DWQXO
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
LK8
M0S
M1P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.3390/v17030378
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection (subscription)
ProQuest Central - New (Subscription)
Natural Science Collection
ProQuest One Community College
Coronavirus Research Database
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Medical Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database (subscription)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals - NZ
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE
CrossRef


Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1999-4915
ExternalDocumentID oai_doaj_org_article_16c42468dd92424cbc3b59dd7de95ec0
PMC11946420
A838686867
40143306
10_3390_v17030378
Genre Journal Article
GeographicLocations Egypt
China
Saudi Arabia
GeographicLocations_xml – name: Egypt
– name: China
– name: Saudi Arabia
GroupedDBID ---
2WC
53G
5VS
7X7
88E
8FE
8FH
8FI
8FJ
A8Z
AADQD
AAFWJ
AAHBH
AAYXX
ABDBF
ABUWG
ACUHS
AFKRA
AFPKN
AFZYC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
BBNVY
BENPR
BHPHI
BPHCQ
BVXVI
CCPQU
CITATION
DIK
E3Z
EBD
ESX
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HMCUK
HYE
IAO
IHR
ITC
KQ8
LK8
M1P
M48
M7P
MODMG
M~E
O5R
O5S
OK1
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RPM
TR2
TUS
UKHRP
CGR
CUY
CVF
ECM
EIF
NPM
PPXIY
PQGLB
PMFND
3V.
7U9
7XB
8FK
AZQEC
COVID
DWQXO
GNUQQ
H94
K9.
PJZUB
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c499t-6d35a48bdb952840ce0f59764aabeeec2449bc3b46d280352f5f8801672e4e993
IEDL.DBID M48
ISSN 1999-4915
IngestDate Wed Aug 27 01:26:15 EDT 2025
Thu Aug 21 18:39:50 EDT 2025
Fri Jul 11 18:54:20 EDT 2025
Fri Jul 25 08:45:49 EDT 2025
Tue Jun 17 21:59:30 EDT 2025
Tue Jun 10 20:53:36 EDT 2025
Sat Jul 12 02:48:53 EDT 2025
Tue Jul 01 05:30:34 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords COVID-19
SARS-CoV-2
viruses
vaccines
healthy
immunization
serological testing
Language English
License https://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c499t-6d35a48bdb952840ce0f59764aabeeec2449bc3b46d280352f5f8801672e4e993
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-5766-4495
0000-0003-0308-8653
0000-0003-3778-8826
0000-0002-5603-1303
OpenAccessLink https://www.proquest.com/docview/3181835225?pq-origsite=%requestingapplication%
PMID 40143306
PQID 3181835225
PQPubID 2032319
ParticipantIDs doaj_primary_oai_doaj_org_article_16c42468dd92424cbc3b59dd7de95ec0
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11946420
proquest_miscellaneous_3181820695
proquest_journals_3181835225
gale_infotracmisc_A838686867
gale_infotracacademiconefile_A838686867
pubmed_primary_40143306
crossref_primary_10_3390_v17030378
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2025-03-06
PublicationDateYYYYMMDD 2025-03-06
PublicationDate_xml – month: 03
  year: 2025
  text: 2025-03-06
  day: 06
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle Viruses
PublicationTitleAlternate Viruses
PublicationYear 2025
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References ref_50
Shields (ref_55) 2021; 100
(ref_69) 2023; 133
ref_14
ref_58
ref_57
Zohar (ref_6) 2020; 20
ref_56
ref_54
Murata (ref_60) 2021; 6
ref_53
Martino (ref_12) 2022; 97
ref_52
ref_51
Ponticelli (ref_64) 2023; 219
ref_19
ref_18
ref_17
ref_16
Fernandes (ref_3) 2023; 156
Taha (ref_2) 2020; 14
Bendavid (ref_29) 2021; 50
He (ref_32) 2023; 14
Rahmadani (ref_33) 2023; 11
ref_25
ref_24
ref_66
He (ref_63) 2022; 101
Fateh (ref_71) 2023; 12
Saeed (ref_26) 2022; 16
Bayram (ref_35) 2021; 93
Richards (ref_61) 2020; 8
Maqsood (ref_65) 2023; 11
Wang (ref_7) 2020; 130
Smits (ref_30) 2023; 41
Zhao (ref_8) 2020; 71
Bourlet (ref_22) 2022; 15
Jaber (ref_78) 2022; 295
Hetta (ref_68) 2021; 25
Shakoor (ref_72) 2021; 144
Filchakova (ref_20) 2022; 244
Taha (ref_1) 2022; 16
Renia (ref_21) 2023; 15
Mukherjee (ref_40) 2021; 16
Mohamed (ref_5) 2021; 15
Yan (ref_59) 2020; 24
Milner (ref_44) 2012; 71
Tsampasian (ref_31) 2023; 183
Accorsi (ref_47) 2022; 327
ref_77
ref_75
ref_74
ref_73
Klein (ref_39) 2015; 109
Franco (ref_23) 2021; 190
Huang (ref_11) 2022; 28
ref_37
Ruggieri (ref_41) 2016; 52
Chauss (ref_70) 2022; 23
Beninger (ref_34) 2023; 45
Khoury (ref_42) 2021; 39
Srivastava (ref_76) 2023; 9
Mishra (ref_38) 2021; 13
Padmavathi (ref_62) 2023; 9
ref_43
Taha (ref_4) 2020; 14
Meyer (ref_10) 2022; 2410
Shakiba (ref_27) 2021; 27
Dinc (ref_15) 2022; 40
Fonseca (ref_36) 2022; 94
Muschiol (ref_28) 2022; 11
ref_49
Pisoschi (ref_67) 2022; 232
Green (ref_46) 2017; 14
ref_48
ref_9
Manna (ref_45) 2015; 13
Anand (ref_13) 2022; 175
References_xml – volume: 71
  start-page: 2027
  year: 2020
  ident: ref_8
  article-title: Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019
  publication-title: Clin. Infect. Dis.
  doi: 10.1093/cid/ciaa344
– ident: ref_50
  doi: 10.3390/vaccines10091462
– ident: ref_49
  doi: 10.3389/fpubh.2022.825874
– ident: ref_51
– ident: ref_57
  doi: 10.3390/vaccines10030414
– volume: 14
  start-page: S406
  year: 2017
  ident: ref_46
  article-title: Obesity Impairs the Adaptive Immune Response to Influenza Virus
  publication-title: Ann. Am. Thorac. Soc.
  doi: 10.1513/AnnalsATS.201706-447AW
– volume: 15
  start-page: 32
  year: 2021
  ident: ref_5
  article-title: Novel coronavirus disease-related knowledge, attitudes, and practices among the residents of Al-Jouf region in Saudi Arabia
  publication-title: J. Infect. Dev. Ctries.
– volume: 41
  start-page: 2447
  year: 2023
  ident: ref_30
  article-title: Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2023.02.038
– volume: 52
  start-page: 198
  year: 2016
  ident: ref_41
  article-title: The influence of sex and gender on immunity, infection and vaccination
  publication-title: Ann. Ist. Super. Sanita.
– ident: ref_74
  doi: 10.3389/fnut.2023.1152254
– ident: ref_77
  doi: 10.3389/fphar.2021.669362
– volume: 232
  start-page: 114175
  year: 2022
  ident: ref_67
  article-title: Antioxidant, anti-inflammatory and immunomodulatory roles of vitamins in COVID-19 therapy
  publication-title: Eur. J. Med. Chem.
  doi: 10.1016/j.ejmech.2022.114175
– ident: ref_73
  doi: 10.3390/medsci12010011
– volume: 16
  start-page: 1432
  year: 2022
  ident: ref_1
  article-title: Role of hospital environmental surfaces in the transmission of the severe acute respiratory syndrome-Coronavirus-2
  publication-title: J. Infect. Dev. Ctries.
  doi: 10.3855/jidc.16572
– volume: 45
  start-page: 387
  year: 2023
  ident: ref_34
  article-title: Drug-drug Interactions: An Overlooked Dimension of the COVID-19 Pandemic
  publication-title: Clin. Ther.
  doi: 10.1016/j.clinthera.2023.04.008
– volume: 11
  start-page: 20503121231158981
  year: 2023
  ident: ref_65
  article-title: Physical activities pre- and post-COVID-19 vaccination and its implementations: A narrative review
  publication-title: SAGE Open Med.
  doi: 10.1177/20503121231158981
– volume: 13
  start-page: 423
  year: 2015
  ident: ref_45
  article-title: Obesity, Oxidative Stress, Adipose Tissue Dysfunction, and the Associated Health Risks: Causes and Therapeutic Strategies
  publication-title: Metab. Syndr. Relat. Disord.
  doi: 10.1089/met.2015.0095
– volume: 295
  start-page: 366
  year: 2022
  ident: ref_78
  article-title: Clinical Trials on Alternative Medicines for COVID-19
  publication-title: Stud. Health Technol. Inform.
– volume: 16
  start-page: 1126
  year: 2022
  ident: ref_26
  article-title: Prevalence of SARS -CoV-2 IgG/IgM antibodies among patients in Zakho City, Kurdistan, Iraq
  publication-title: J. Infect. Dev. Ctries.
  doi: 10.3855/jidc.15825
– volume: 71
  start-page: 298
  year: 2012
  ident: ref_44
  article-title: The impact of obesity on the immune response to infection
  publication-title: Proc. Nutr. Soc.
  doi: 10.1017/S0029665112000158
– volume: 244
  start-page: 123409
  year: 2022
  ident: ref_20
  article-title: Review of COVID-19 testing and diagnostic methods
  publication-title: Talanta
  doi: 10.1016/j.talanta.2022.123409
– ident: ref_14
  doi: 10.3390/vaccines9091047
– volume: 94
  start-page: 2139
  year: 2022
  ident: ref_36
  article-title: Dynamics of antibody response to CoronaVac vaccine
  publication-title: J. Med. Virol.
  doi: 10.1002/jmv.27604
– volume: 12
  start-page: 269
  year: 2023
  ident: ref_71
  article-title: The Effect of Vit-D Supplementation on the Side Effect of BioNTech, Pfizer Vaccination and Immunoglobulin G Response Against SARS-CoV-2 in the Individuals Tested Positive for COVID-19: A Randomized Control Trial
  publication-title: Clin. Nutr. Res.
  doi: 10.7762/cnr.2023.12.4.269
– ident: ref_52
– volume: 14
  start-page: 1095
  year: 2020
  ident: ref_2
  article-title: The Severe Acute Respiratory Syndrome Coronavirus-2 Pandemic: An Overview to Control Human-wildlife and Human-human Interactions
  publication-title: J. Pure Appl. Microbiol.
  doi: 10.22207/JPAM.14.2.02
– volume: 327
  start-page: 639
  year: 2022
  ident: ref_47
  article-title: Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants
  publication-title: JAMA
  doi: 10.1001/jama.2022.0470
– ident: ref_75
  doi: 10.3389/fnut.2023.1161894
– volume: 2410
  start-page: 27
  year: 2022
  ident: ref_10
  article-title: Principles in Immunology for the Design and Development of Vaccines
  publication-title: Methods Mol. Biol.
  doi: 10.1007/978-1-0716-1884-4_2
– ident: ref_37
  doi: 10.1128/spectrum.01181-21
– ident: ref_53
  doi: 10.3390/vaccines10020292
– volume: 9
  start-page: e21205
  year: 2023
  ident: ref_76
  article-title: Promising role of Vitamin D and plant metabolites against COVID-19: Clinical trials review
  publication-title: Heliyon
  doi: 10.1016/j.heliyon.2023.e21205
– volume: 144
  start-page: 108
  year: 2021
  ident: ref_72
  article-title: Be well: A potential role for vitamin B in COVID-19
  publication-title: Maturitas
  doi: 10.1016/j.maturitas.2020.08.007
– ident: ref_58
  doi: 10.3389/fimmu.2021.737083
– volume: 28
  start-page: 214.e1
  year: 2022
  ident: ref_11
  article-title: Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation
  publication-title: Transplant. Cell. Ther.
  doi: 10.1016/j.jtct.2022.01.019
– volume: 109
  start-page: 9
  year: 2015
  ident: ref_39
  article-title: Sex-based differences in immune function and responses to vaccination
  publication-title: Trans. R. Soc. Trop. Med. Hyg.
  doi: 10.1093/trstmh/tru167
– volume: 101
  start-page: e29438
  year: 2022
  ident: ref_63
  article-title: Association between smoking and COVID-19 severity: A multicentre retrospective observational study
  publication-title: Medicine
  doi: 10.1097/MD.0000000000029438
– volume: 133
  start-page: 6
  year: 2023
  ident: ref_69
  article-title: Vitamin D and SARS-CoV-2
  publication-title: Basic Clin. Pharmacol. Toxicol.
  doi: 10.1111/bcpt.13872
– volume: 97
  start-page: 30
  year: 2022
  ident: ref_12
  article-title: SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group
  publication-title: Am. J. Hematol.
  doi: 10.1002/ajh.26385
– volume: 11
  start-page: e1379
  year: 2022
  ident: ref_28
  article-title: Probabilistic classification of anti-SARS-CoV-2 antibody responses improves seroprevalence estimates
  publication-title: Clin. Transl. Immunol.
  doi: 10.1002/cti2.1379
– volume: 14
  start-page: 892
  year: 2023
  ident: ref_32
  article-title: Correlation between COVID-19 vaccination and diabetes mellitus: A systematic review
  publication-title: World J. Diabetes
  doi: 10.4239/wjd.v14.i6.892
– ident: ref_56
  doi: 10.1186/s12916-022-02547-2
– volume: 6
  start-page: e00019-21
  year: 2021
  ident: ref_60
  article-title: Shedding of Viable Virus in Asymptomatic SARS-CoV-2 Carriers
  publication-title: mSphere
  doi: 10.1128/mSphere.00019-21
– volume: 9
  start-page: e20792
  year: 2023
  ident: ref_62
  article-title: Tobacco smoking model containing snuffing class
  publication-title: Heliyon
  doi: 10.1016/j.heliyon.2023.e20792
– volume: 25
  start-page: 2131
  year: 2021
  ident: ref_68
  article-title: The interplay between vitamin D and COVID-19: Protective or bystander?
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– ident: ref_9
  doi: 10.1016/j.biopha.2021.111254
– volume: 190
  start-page: 161
  year: 2021
  ident: ref_23
  article-title: COVID-19 in Health-Care Workers: A Living Systematic Review and Meta-Analysis of Prevalence, Risk Factors, Clinical Characteristics, and Outcomes
  publication-title: Am. J. Epidemiol.
  doi: 10.1093/aje/kwaa191
– ident: ref_24
  doi: 10.3390/vaccines11010026
– ident: ref_25
  doi: 10.3390/ijerph19127119
– volume: 39
  start-page: 6984
  year: 2021
  ident: ref_42
  article-title: COVID-19 vaccine—Long term immune decline and breakthrough infections
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2021.10.038
– ident: ref_18
– volume: 15
  start-page: e16345
  year: 2023
  ident: ref_21
  article-title: Acquired immunity against SARS-CoV-2 infection and vaccination
  publication-title: EMBO Mol. Med.
  doi: 10.15252/emmm.202216345
– ident: ref_54
  doi: 10.3390/ijerph192416803
– volume: 15
  start-page: 1170
  year: 2022
  ident: ref_22
  article-title: Role of the humoral immune response during COVID-19: Guilty or not guilty?
  publication-title: Mucosal Immunol.
  doi: 10.1038/s41385-022-00569-w
– volume: 219
  start-page: 18
  year: 2023
  ident: ref_64
  article-title: Smoking habits predict adverse effects after mRNA COVID-19 vaccine: Empirical evidence from a pilot study
  publication-title: Public Health
  doi: 10.1016/j.puhe.2023.03.013
– volume: 40
  start-page: 52
  year: 2022
  ident: ref_15
  article-title: Inactive SARS-CoV-2 vaccine generates high antibody responses in healthcare workers with and without prior infection
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2021.11.051
– ident: ref_48
  doi: 10.3389/fendo.2022.898810
– volume: 8
  start-page: 664
  year: 2020
  ident: ref_61
  article-title: Tobacco smoking and COVID-19 infection
  publication-title: Lancet Respir. Med.
  doi: 10.1016/S2213-2600(20)30239-3
– volume: 20
  start-page: 392
  year: 2020
  ident: ref_6
  article-title: Dissecting antibody-mediated protection against SARS-CoV-2
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/s41577-020-0359-5
– ident: ref_17
  doi: 10.3389/fmed.2021.778129
– volume: 100
  start-page: 1220
  year: 2021
  ident: ref_55
  article-title: COVID-19: Seroprevalence and Vaccine Responses in UK Dental Care Professionals
  publication-title: J. Dent. Res.
  doi: 10.1177/00220345211020270
– volume: 23
  start-page: 62
  year: 2022
  ident: ref_70
  article-title: Autocrine vitamin D signaling switches off pro-inflammatory programs of TH1 cells
  publication-title: Nat. Immunol.
  doi: 10.1038/s41590-021-01080-3
– volume: 130
  start-page: 5235
  year: 2020
  ident: ref_7
  article-title: Kinetics of viral load and antibody response in relation to COVID-19 severity
  publication-title: J. Clin. Investig.
  doi: 10.1172/JCI138759
– ident: ref_16
  doi: 10.3389/fimmu.2021.802858
– volume: 27
  start-page: 636
  year: 2021
  ident: ref_27
  article-title: Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020
  publication-title: Emerg. Infect. Dis.
  doi: 10.3201/eid2702.201960
– ident: ref_66
  doi: 10.3390/ijerph20065183
– volume: 156
  start-page: 148
  year: 2023
  ident: ref_3
  article-title: Influence of age, gender, previous SARS-CoV-2 infection, and pre-existing diseases in antibody response after COVID-19 vaccination: A review
  publication-title: Mol. Immunol.
  doi: 10.1016/j.molimm.2023.03.007
– volume: 175
  start-page: 371
  year: 2022
  ident: ref_13
  article-title: SARS-CoV-2 Vaccine Antibody Response and Breakthrough Infection in Patients Receiving Dialysis
  publication-title: Ann. Intern. Med.
  doi: 10.7326/M21-4176
– volume: 16
  start-page: 38
  year: 2021
  ident: ref_40
  article-title: Is COVID-19 Gender-sensitive?
  publication-title: J. Neuroimmune Pharmacol.
  doi: 10.1007/s11481-020-09974-z
– volume: 11
  start-page: e15072
  year: 2023
  ident: ref_33
  article-title: Potential drug-drug interactions and their associated factors in hospitalized COVID-19 patients with comorbidities
  publication-title: PeerJ
  doi: 10.7717/peerj.15072
– volume: 183
  start-page: 566
  year: 2023
  ident: ref_31
  article-title: Risk Factors Associated With Post-COVID-19 Condition: A Systematic Review and Meta-analysis
  publication-title: JAMA Intern. Med.
  doi: 10.1001/jamainternmed.2023.0750
– volume: 13
  start-page: e19879
  year: 2021
  ident: ref_38
  article-title: Waning of Anti-spike Antibodies in AZD1222 (ChAdOx1) Vaccinated Healthcare Providers: A Prospective Longitudinal Study
  publication-title: Cureus
– volume: 50
  start-page: 410
  year: 2021
  ident: ref_29
  article-title: COVID-19 antibody seroprevalence in Santa Clara County, California
  publication-title: Int. J. Epidemiol.
  doi: 10.1093/ije/dyab010
– ident: ref_19
– ident: ref_43
– volume: 14
  start-page: 2287
  year: 2020
  ident: ref_4
  article-title: Can COVID-19 Be Transmitted Sexually by Semen?
  publication-title: J. Pure Appl. Microbiol.
  doi: 10.22207/JPAM.14.4.06
– volume: 93
  start-page: 5560
  year: 2021
  ident: ref_35
  article-title: Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers
  publication-title: J. Med. Virol.
  doi: 10.1002/jmv.27098
– volume: 24
  start-page: 245
  year: 2020
  ident: ref_59
  article-title: Duration of SARS-CoV-2 viral RNA in asymptomatic carriers
  publication-title: Crit. Care
  doi: 10.1186/s13054-020-02952-0
SSID ssj0066907
Score 2.378424
Snippet It is essential to comprehend the humoral immune response to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its vaccines to maximize the...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 378
SubjectTerms Adaptive immunity
Adolescent
Adult
Antibodies
Antibodies, Viral - blood
Anticoagulants
Asymptomatic
B cells
College students
Comorbidity
Coronaviruses
COVID-19
COVID-19 - epidemiology
COVID-19 - immunology
COVID-19 - prevention & control
COVID-19 vaccines
COVID-19 Vaccines - administration & dosage
COVID-19 Vaccines - immunology
Cross-Sectional Studies
Dietary supplements
Disease transmission
Egypt - epidemiology
Enzyme-linked immunosorbent assay
Enzymes
Ethylenediaminetetraacetic acid
Female
Health aspects
healthy
Herbs
Humans
Immune response
Immune response (humoral)
Immunity (Disease)
immunization
Immunoassay
Immunoglobulin G
Immunoglobulin G - blood
Immunoglobulin M
Immunoglobulin M - blood
Immunoglobulins
Immunology
Immunostimulants
Infections
Lymphocytes
Male
Microbiota
Pandemics
Physical activity
Physiological aspects
Sample size
SARS-CoV-2
SARS-CoV-2 - immunology
Seroepidemiologic Studies
serological testing
Serology
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Statistical analysis
Students
Students - statistics & numerical data
Universities
Vaccination
Vaccination - statistics & numerical data
Vaccines
Viruses
Vitamins
Young Adult
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals - NZ
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQJSQuCMor0FYGIXGydpPYTsItrLa0SO2BpVVvkT12yl4SRLdI_RP8Zmbs7DYRBy4op8QTyZ6HZ0aamY-x91UBGBc7EKCNFVKCErYCEEZb07rCtm3ocj071ycX8suVuhpBfVFNWBwPHBk3SzXITOrSuYo6GcBCblXlXOF8pTyEbB193jaZinewppwvzhHKMamf_UpJsXPCUht5nzCk_--reOSLpnWSI8dz_IQ9HiJGXsedPmUPfLfPHkYMybtn7PcSjTT2H_K-5XW3WYtV_XUlFv2lyPjp9dns9PozxzuB8E5Qr8iUeU0YQ_y878SlAVh3GHE6bjrHR6_3NRt8FSdg3nzkNV_QycQqlHDRxpYEZIZKFojunrOL4-W3xYkYQBYEYLKzEdrlysjSOlspdFVz8PMWkwwtjbHee0D3XxHPpXYEZKWyVrVo86kuMi89Rjcv2F7Xd_4V4wqFlIH0MvSnAliDckNfYCyKHD8k7N2W-c2POEujwRyEJNTsJJSwTySWHQGNvw4fUCmaQSmafylFwj6QUBsyUpQcmKHXAPdJ466ausxLTU-RsIMJJRoXTJe3atEMxn3T4DWYhsBVJeztbpn-pIK1zve3A0021xXSvIxatDuSpJmKmKolrJzo1-TM05Vu_T2M_k7TSmLGOH_9P7j0hj3KCM044EkesL3Nz1t_iCHWxh4Fa_oDNIcnGQ
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fb9MwELZgCIkXxG8CAxmExJPVNLGdhBcUqo4NaXugbOpbZJ-d0pdkrB3S_gn-Zu6cNGuEhPqU-FLZve_su_TuPsY-FBmgX-xAgDZWSAlK2AJAGG1N7TJb16HK9fRMH5_Lb0u17F-4bfq0yt2eGDZq1wK9I58g9qbBW1CfL38JYo2if1d7Co277B61LiNUZ8sh4NIU-XXdhFIM7Se_pwTvlBjV9s6g0Kr_3w1570QaZ0vuHT9Hj9jD3m_kZafox-yOb56w-x2T5M1T9meOptpVIfK25mWzXYtF-X0hZu2FSPjJ6nRysvrKcWcg1hNEFxk0L4lpiJ-1jbgwAOsG_U7HTeP43uVt5gZfdH0wN594yWe0MrEIiVw0sTnRmSHUgtDNM3Z-NP8xOxY91YIADHm2QrtUGZlbZwuFB1YMPq4x1NDSGOu9B3QCCgupldoRnZVKalWj5U91lnjp0cd5zg6atvEvGVe5cwlIL0OVKoA1Uud4IhiLiscbEXu_-_Gry66jRoWRCGmoGjQUsS-klkGAmmCHG-3VquptqppqkAl-uXMFFbkATVAVzmXOF8pDHLGPpNSKTBU1B6avOMB5UtOrqszTXNMni9jhSBJNDMbDO1hUvYlvqltARuzdMExPUtpa49vrXiaJdYEyLzoUDUuS1FkRA7aI5SN8jdY8HmnWP0MDcMS6xLgxfvX_eb1mDxJiKw58kYfsYHt17d-gC7W1b4Od_AVEDR4R
  priority: 102
  providerName: ProQuest
Title Estimation of Anti-SARS-CoV-2 IgM/IgG Seroprevalence Among Non-Vaccinated and Vaccinated University Students: A Cross-Sectional Egyptian Study
URI https://www.ncbi.nlm.nih.gov/pubmed/40143306
https://www.proquest.com/docview/3181835225
https://www.proquest.com/docview/3181820695
https://pubmed.ncbi.nlm.nih.gov/PMC11946420
https://doaj.org/article/16c42468dd92424cbc3b59dd7de95ec0
Volume 17
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3ri9NAEF_ugeAX8X3Rs6wi-Gm9Jt3dJIJIrvQeQotc7dFvYV-pBUm01xP7T_g3O7NJY4N-kEAgu5Owm5nZmUl25kfI6zQ24Bdbw4xUmnFuBNOpMUxJrQob66LwWa7jibyY8Y9zMd8jW4zN5gXe_DO0Qzyp2err25_fNx9A4d9jxAkh-8mPEMV2ECf75BAMUoxABmPe_kyQGAD6n8spAqqFoi4w1L21Y5Z89f6_1-gdI9XdQLljkc7uk3uNK0mzmvcPyJ4rH5I7Nbjk5hH5NQLtrRMTaVXQrFwv2TS7mrJhdc0ierkYn1wuziksFgiEAgKHOk4zBB-ik6pk18qYZQmuqKWqtHTn8s9mDjqtS2PevKMZHeLM2NTv7cKBjRDhDKTPE20ek9nZ6PPwgjXoC8xAFLRm0g6E4om2OhVgw_rG9QuIPiRXSjvnDPgFqTYDzaVFhCsRFaKAxSCUceS4A7fnCTkoq9IdESoSayPDHfeJq8ZoxWUCRkJpkAVoCMir7cvPv9VFNnIITpBDecuhgJwiW1oCrIvtG6rVIm_ULA-l4RE83NoU814MDlCk1sbWpcKZfkDeIFNzlCfgnFFNEgKME-tg5VkySCQecUCOO5SgdabbvRWLfCu0OayPofdoRUBett14J-5kK11129BEfZkCzdNaitopcSy2CDFcQJKOfHXm3O0pl198TfAwTDmEkv1n_z3B5-RuhFjGHk3ymBysV7fuBThYa90j-_E87pHD09Hk01XPf6aA8_k87HnF-g0THioJ
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF5VRQguiDeGAgsCcVrVj_Xai4SQCSkJbXIgbZWb63045GKXJgXlT_BT-I3MrJ00FhK3Kid7x9Fu5u3MzEfIG5loiIuNZloUinGuY6ak1qwQqihNosrSdbmOxmJwwr9O4-kO-bPuhcGyyrVNdIba1Brfke-D7AUuWog_nv9giBqF_66uITQasTi0q1-Qsi0-DD8Df9-G4UH_uDdgLaoA0xDdL5kwUVzwVBklY7DNvrZ-CVG14EWhrLUa_J1UOlJcGERuisMyLkHIA5GElluJw5fA5N8Ax-tjspdMNwmewEyzmV4URdLf_xmgOkWI4Lbl8xw0wL8OYMsDdqszt9zdwV1yp41TadYI1j2yY6v75GaDXLl6QH73wTQ0XY-0LmlWLedskn2bsF59ykI6nI32h7MvFCwRoqyANKMBoRkiG9FxXbHTQut5BXGuoUVl6NblVaUInTRzNxfvaUZ7eDI2cYVjuLE-wqeBaDui1UNyci1MeER2q7qyTwiNU2NCzS13XbFaq4KLFDxQoUDQ4IZHXq9__Py8meCRQ-aDHMo3HPLIJ2TLhgCHbrsb9cUsb3U4D4TmIXy5MRKbajRuMJbGJMbK2GrfI--QqTmaBuCcLtoOB9gnDtnKszRKBX4Sj-x1KEGldXd5LRZ5a1IW-ZUCeOTVZhmfxDK5ytaXLU3oCwk0jxsp2hyJ4yRHSBA9knbkq3Pm7ko1_-4GjgeB5JCn-k__v6-X5NbgeHSUHw3Hh8_I7RCRkh1W5R7ZXV5c2ucQvi3VC6czlJxdt5L-BfSbWoY
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF5VqUBcEG8MBRYE4rSKH-u1FwkhN01oKI2qhla9ud6HQy52aVJQ_gQ_iF_HjB9pLCRuVU72jqPdzNuZmY-QtzLSEBcbzbTIFONch0xJrVkmVJabSOV51eV6OBH7J_zLWXi2Rf60vTBYVtnaxMpQm1LjO_I-yJ5XRQthP2_KIo72Rp8ufjBEkMJ_Wls4jVpEDuzqF6Rvi4_jPeD1O98fDb8N9lmDMMA0RPpLJkwQZjxWRskQ7LSrrZtDhC14lilrrQbfJ5UOFBcGUZxCPw9zEHhPRL7lVuIgJjD_2xFmRT2yvTucHB23fkBg3lnPMgoC6fZ_eqhcAeK5bXjACijgX3ew4Q-7tZobzm90j9xtolaa1GJ2n2zZ4gG5VeNYrh6S30MwFHUPJC1zmhTLOZsmx1M2KE-ZT8ezw_549pmCXULMFZBtNCc0QZwjOikLdpppPS8g6jU0KwzduLyuG6HTegrn4gNN6ABPxqZVGRlubIhgaiDoFdHqETm5ETY8Jr2iLOxTQsPYGF9zy6seWa1VxkUM_ihTIHZwwyFv2h8_vajneaSQByGH0jWHHLKLbFkT4Aju6kZ5OUsbjU49obkPX26MxBYbjRsMpTGRsTK02nXIe2RqioYCOKezpt8B9okjt9IkDmKBn8ghOx1KUHDdXW7FIm0MzCK9VgeHvF4v45NYNFfY8qqh8V0hgeZJLUXrI3Gc6wjpokPijnx1ztxdKebfq_Hjnic5ZK3us__v6xW5DQqafh1PDp6TOz7CJlfAlTukt7y8si8glluql43SUHJ-03r6F-U4YCE
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Estimation+of+Anti-SARS-CoV-2+IgM%2FIgG+Seroprevalence+Among+Non-Vaccinated+and+Vaccinated+University+Students%3A+A+Cross-Sectional+Egyptian+Study&rft.jtitle=Viruses&rft.au=Taha%2C+Ahmed+E&rft.au=Amer%2C+Ibrahim&rft.au=Sharawy%2C+Shimaa+El&rft.au=Ghazy%2C+Amany+A&rft.date=2025-03-06&rft.pub=MDPI+AG&rft.issn=1999-4915&rft.eissn=1999-4915&rft.volume=17&rft.issue=3&rft_id=info:doi/10.3390%2Fv17030378&rft.externalDocID=A838686867
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1999-4915&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1999-4915&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1999-4915&client=summon